Dopaminergic agonists for hepatic encephalopathy (Q24245819)

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Marginal modeling of binary cross-over data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

False neurotransmitters and hepatic failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Genetic associations in large versus small studies: an empirical assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Levodopa in hepatic coma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Levodopa in fulminant hepatic failure: preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003047.PUB2